Comparison · NCT00004978-ecad9550
rIL-2 vs No rIL-2: Participants With a New Disease Progression Event or Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. rIL-2 vs No rIL-2: Participants With a New Disease Progression Event or Death. Trial comparisons, record NCT00004978-ecad9550. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00004978-ecad9550
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0744 | 0.0638 | 0.0865 | wilson | |
| Risk in group 2 | 0.0804 | 0.0694 | 0.093 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00603 | -0.0225 | 0.0103 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.925 | 0.749 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.919 | 0.731 | 1.16 | log | |
| Number needed to treat, for one fewer participant with the outcome on rIL-2 than on No rIL-2 | 166 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | rIL-2 | Subcutaneous recombinant interleukin-2 (rIL-2) therapy | 154 | 2,071 | OG000 |
| Group 2 | No rIL-2 | Control group - no study-assigned medication | 164 | 2,040 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants With a New Disease Progression Event or Death
- Description
Includes first new episode of: CDC Category C 1993 AIDS-defining events plus invasive aspergillosis, bartonellosis, Chagas disease, Herpes zoster, visceral Leishmaniasis, Hodgkin's lymphoma, non-Hodgkin's lymphoma (all cell types), microsporidiosis, nocardiosis, disseminated Penicillium marneffii, extrapulmonary Pneumocystis carinii, and Rhodococcus equi disease
- Time frame
- from randomization through 15 November 2008 - median of 7.6 years follow-up
- Population
Source ClinicalTrials.gov
Trial
- Title
- An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
- NCT number
- NCT00004978
- Phases
- PHASE3
- Conditions
- HIV Infections
- Interventions
- Recombinant interleukin-2 (rIL-2)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2011-04-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00004978?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00004978-ecad9550